Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evaxion Biotech ( (EVAX) ) has shared an announcement.
On August 27, 2025, Evaxion A/S announced its participation in several scientific and investor conferences across the US, Europe, and Asia during the latter half of 2025. This strategic engagement aims to present their data and discoveries, particularly the two-year clinical data for their personalized cancer vaccine EVX-01, and to explore potential business partnerships and scientific collaborations. The company’s presence at these conferences is expected to enhance its stakeholder engagement and industry positioning.
The most recent analyst rating on (EVAX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall stock score is driven by strong technical momentum and positive earnings call insights, offset by financial instability and poor valuation metrics. The company’s significant revenue growth is promising, but financial challenges and reliance on debt pose risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion is a pioneering TechBio company based in Denmark, specializing in AI-Immunology™ powered vaccines. The company utilizes its proprietary AI platform to develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion is focused on transforming patient lives through innovative and targeted treatment options, with a clinical-stage oncology pipeline and a preclinical infectious disease pipeline.
Average Trading Volume: 113,270
Technical Sentiment Signal: Sell
Current Market Cap: $19.64M
For a thorough assessment of EVAX stock, go to TipRanks’ Stock Analysis page.